252 related articles for article (PubMed ID: 23721490)
1. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
El Sayed I; Helmy MW; El-Abhar HS
Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
7. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Cheng CC; Chao WT; Shih JH; Lai YS; Hsu YH; Liu YH
Cancer Chemother Pharmacol; 2021 Jul; 88(1):143-153. PubMed ID: 33860837
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
12. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
13. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
14. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.
Lau GM; Lau GM; Yu GL; Gelman IH; Gutowski A; Hangauer D; Fang JW
Dig Dis Sci; 2009 Jul; 54(7):1465-74. PubMed ID: 18979199
[TBL] [Abstract][Full Text] [Related]
15. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]